361 related articles for article (PubMed ID: 21665252)
21. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
22. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs.
Liu SQ; Wiradharma N; Gao SJ; Tong YW; Yang YY
Biomaterials; 2007 Mar; 28(7):1423-33. PubMed ID: 17141308
[TBL] [Abstract][Full Text] [Related]
23. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
[TBL] [Abstract][Full Text] [Related]
24. Nanoscaled poly(L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer.
Li M; Song W; Tang Z; Lv S; Lin L; Sun H; Li Q; Yang Y; Hong H; Chen X
ACS Appl Mater Interfaces; 2013 Mar; 5(5):1781-92. PubMed ID: 23410916
[TBL] [Abstract][Full Text] [Related]
25. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
26. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
[TBL] [Abstract][Full Text] [Related]
27. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
28. Actively targeted delivery of doxorubicin to bone metastases by a pH-sensitive conjugation.
Ye WL; Zhao YP; Na R; Li F; Mei QB; Zhao MG; Zhou SY
J Pharm Sci; 2015 Jul; 104(7):2293-303. PubMed ID: 25980534
[TBL] [Abstract][Full Text] [Related]
29. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.
Li SD; Howell SB
Mol Pharm; 2010 Feb; 7(1):280-90. PubMed ID: 19994852
[TBL] [Abstract][Full Text] [Related]
30. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles.
Kim TH; Mount CW; Gombotz WR; Pun SH
Biomaterials; 2010 Oct; 31(28):7386-97. PubMed ID: 20598741
[TBL] [Abstract][Full Text] [Related]
31. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
32. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound.
Gao ZG; Fain HD; Rapoport N
J Control Release; 2005 Jan; 102(1):203-22. PubMed ID: 15653146
[TBL] [Abstract][Full Text] [Related]
33. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
34. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells.
Ai S; Duan J; Liu X; Bock S; Tian Y; Huang Z
Mol Pharm; 2011 Apr; 8(2):375-86. PubMed ID: 21241067
[TBL] [Abstract][Full Text] [Related]
35. Thermosensitive Injectable Hydrogel for Simultaneous Intraperitoneal Delivery of Doxorubicin and Prevention of Peritoneal Adhesion.
Chen CH; Kuo CY; Chen SH; Mao SH; Chang CY; Shalumon KT; Chen JP
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734717
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts.
Zou C; Brewer M; Cao X; Zang R; Lin J; Deng Y; Li C
Gynecol Oncol; 2007 Dec; 107(3):441-9. PubMed ID: 17854871
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis.
Pourgholami MH; Akhter J; Wang L; Lu Y; Morris DL
Cancer Chemother Pharmacol; 2005 May; 55(5):425-32. PubMed ID: 15565325
[TBL] [Abstract][Full Text] [Related]
38. The influence of ovarian cancer induced peritoneal carcinomatosis on the pharmacokinetics of albendazole in nude mice.
Pourgholami MH; Cai ZY; Chu SW; Galettis P; Morris DL
Anticancer Res; 2010 Feb; 30(2):423-8. PubMed ID: 20332449
[TBL] [Abstract][Full Text] [Related]
39. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization.
Tinkov S; Coester C; Serba S; Geis NA; Katus HA; Winter G; Bekeredjian R
J Control Release; 2010 Dec; 148(3):368-72. PubMed ID: 20868711
[TBL] [Abstract][Full Text] [Related]
40. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]